BNP Paribas Financial Markets Buys 534,626 Shares of Roivant Sciences Ltd. $ROIV

BNP Paribas Financial Markets boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 30.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,294,506 shares of the company’s stock after acquiring an additional 534,626 shares during the period. BNP Paribas Financial Markets’ holdings in Roivant Sciences were worth $49,791,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund lifted its stake in Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares during the period. Bessemer Group Inc. lifted its stake in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Allworth Financial LP lifted its stake in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Fifth Third Bancorp lifted its stake in Roivant Sciences by 15.8% in the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares during the period. Finally, Utah Retirement Systems lifted its stake in Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after buying an additional 600 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Guggenheim boosted their price target on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research report on Friday, March 20th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Insider Buying and Selling

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $48,827,417.01. This represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 945,173 shares of company stock valued at $27,654,456. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Stock Down 2.9%

Shares of NASDAQ:ROIV opened at $28.25 on Wednesday. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $32.79. The stock’s 50 day moving average is $28.65 and its 200-day moving average is $25.48. The firm has a market capitalization of $20.32 billion, a price-to-earnings ratio of -47.08 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the firm posted ($0.29) EPS. Equities research analysts anticipate that Roivant Sciences Ltd. will post -1.06 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.